Published in final edited form as:

Atherosclerosis. 2015 June ; 240(2): 431–436. doi:10.1016/j.atherosclerosis.2015.03.043.

Red Blood Cell Fatty Acids and Biomarkers of Inflammation: A Cross-sectional Study in a Community-based Cohort

João D. Fontes^{a,b,†}, Faisal Rahman^{c,†}, Sean Lacey^a, Martin G. Larson^{a,d,e}, Ramachandran S. Vasan^{a,b,f}, Emelia J. Benjamin^{a,b,f}, William S. Harris^{g,*}, and Sander J. Robins^{a,b}

^a National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA, USA

^b Departments of Cardiology and Preventive Medicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA

^c Boston University Medical Center, Boston, MA 02118

^d Department of Mathematics and Statistics, Boston University, Boston, MA, USA

^e Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA

^f Epidemiology Department, Boston University School of Public Health, Boston, MA, USA

^g Department of Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD.

Abstract

Introduction—Inflammation and inflammatory biomarkers have emerged as integral components and predictors of incident cardiovascular (CV) disease. Omega-3 fatty acids, particularly eicosapentaenoic and docosahexaenoic acids (EPA and DHA) have anti-inflammatory properties, and have been variably associated with lower blood pressure, favorable blood lipid changes, and reduced CV events.

Methods and Results—We examined the cross-sectional association of red blood cell (RBC) fatty acids, representative of body membrane fatty acid composition, with 10 biomarkers active in multiple inflammatory pathways in 2724 participants (mean age 66±9 years, 54% women, 8% minorities) from the Framingham Offspring and minority Omni Cohorts. . After multivariable adjustment, the RBC EPA and DHA content was inversely correlated (all $P < 0.001$) with 8 markers of inflammation, receptors, or pathways: urinary isoprostanes ($r=-0.16$); and soluble interleukin-6 ($r=-0.10$); C-reactive protein ($r=-0.08$); tumor necrosis factor receptor 2 ($r=-0.08$); intercellular

* Corresponding author 5009 W. 12th St, Ste 8, Sioux Falls, SD 57106, 605-277-4293, bill.harris@usd.edu.

†First authors

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of Interest:

W.S.H. is a member of the scientific advisory board of Aker Biomarine. He is the President of OmegaQuant Analytics, LLC, and is a Senior Research Scientist at Health Diagnostic Laboratory, Inc., two companies that offer blood omega-3 fatty acid testing. Other authors have no conflicts of interest to disclose.

adhesion molecule-1 ($r=-0.08$); P-selectin ($r=-0.06$); lipoprotein-associated phospholipase-A2 mass ($r=-0.11$) and activity ($r=-0.08$). The correlations for monocyte chemoattractant protein-1 was -0.05 , $P=0.006$ and osteoprotegerin ($r=-0.06$, $P=0.002$) were only nominally significant.

Conclusion—In our large community-based study, we observed modest inverse associations between several types of inflammatory biomarkers with RBC omega-3 fatty acid levels. Our findings are consistent with the hypothesis that omega-3 fatty acids have anti-inflammatory properties.

Keywords

omega-3 fatty acids; biomarkers; inflammation; cross-sectional study

Introduction

Higher fish and fish oil consumption have been variably reported to be associated with decreased cardiovascular (CV) events¹, strokes^{2, 3}, and dementia⁴. The major reason for the benefits of fish consumption is considered to be their content of omega-3 (ω -3) long chain polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)⁵⁻⁷. The biological mechanisms responsible for the potential protective effects of EPA and DHA are incompletely understood.

The role of inflammation in atherosclerosis is well-established^{8, 9}. More recently studies have demonstrated associations of inflammatory markers with many other conditions such as hypertension¹⁰, dyslipidemia¹¹, diabetes mellitus¹², atrial fibrillation¹³, and chronic renal disease¹⁴. ω -3 PUFAs may modify inflammatory cascades favorably, which may be an important factor in their protective role, but published results in intervention studies have been inconsistent¹⁵.

Other cohorts that have examined the correlations between omega-3 biostatus and inflammatory markers have been from cultures differing substantially in diet and lifestyle from the US (e.g., Tuscany, Japan, Korea, Finland) (Table 3), and although the findings are relatively consistent, the relations observed there may not reflect the US situation. The largest US study (prior to the present one) to examine these associations was the Multiethnic Study of Atherosclerosis (MESA)^{16, 17}. However, these investigators used plasma phospholipid EPA and DHA levels as their marker of exposure and examined relations with only six inflammatory biomarkers. The within person variability for EPA+DHA levels in plasma phospholipids is four times higher than that of red blood cells (RBC)¹⁸, and as such, some true associations may have been missed. To avoid this concern and to expand upon the number of biomarkers examined in MESA, we used RBC EPA+DHA levels for our analyses which reflect relatively long-term tissue omega-3 status, much like hemoglobin A1c is used to monitor glycemic status¹⁹. We have assessed the relations between ω -3 PUFA status and 10 biomarkers representing different phases and pathways of inflammation in a large, community-based sample. We hypothesized that the RBC EPA+DHA content is inversely correlated with serum concentrations of several inflammatory biomarkers.

Methods

Study Sample

The Framingham Heart Study is a longitudinal community-based cohort study that was initiated in 1948. The selection criteria for the Framingham Offspring Cohort and the Framingham Omni Cohort have previously been described^{20, 21} (<http://nhlbi.nih.gov/about/framingham>). Briefly, adult children of the Original cohort were recruited in 1971 into the Framingham Offspring Cohort. To reflect the increased diversity of the community as the population has changed in Framingham, the ethnic/racial minority Omni cohort was recruited in 1994²². We evaluated Framingham Offspring participants ($n = 3021$) who attended their eighth examination cycle (2005-2008) and Framingham Omni participants ($n = 298$) who attended their third examination (2007-2008). Participants were excluded in hierarchical order if they were missing RBC fatty acid measurements ($n = 123$), biomarker measurements ($n = 323$), or clinical covariates ($n = 149$). The study protocol was approved by the Institutional Review Board of the Boston University Medical Center. Informed consent was provided by all participants.

Omega-3 Index

Blood was drawn after a 10-12 hour fast into an EDTA tube, and RBCs were separated from plasma by centrifugation. The RBC fraction was frozen at -80°C immediately after collection. RBC fatty acid composition was determined as described previously²³. Briefly, RBCs were incubated at 100°C with boron trifluoride-methanol and hexane to generate fatty acid methyl esters that were then analyzed by gas chromatography with flame ionization detection. The omega-3 index was defined as EPA+DHA as a percent of the total fatty acids in RBC membranes²⁴. The coefficients of variation were 6.2% for EPA, 4.4% for DHA, and 3.2% for the omega-3 index.

Inflammatory Biomarkers

We selected one urinary and nine serum biomarkers representing multiple inflammatory pathways: urinary 8-epi-PGF₂ α isoprostanes (normalized to creatinine), C-reactive protein (CRP), interleukin-6, intercellular adhesion molecule-1 (ICAM-1), lipoprotein-associated phospholipase-A2 (LpPLA2) activity and mass, monocyte chemoattractant protein-1 (MCP-1), osteoprotegerin, P-selectin, and tumor necrosis factor receptor 2 (TNFR2). The details of the rationale for selection of these biomarkers, assays and measurements have been described previously²⁵. The inter-assay coefficients of variation were less than 10% for all measurements.¹³

Statistical analyses

Descriptive statistics are presented as percentage for categorical variables and as mean $\pm$ standard deviation for continuous variables. To normalize skewed distributions, analyses of inflammatory biomarkers were natural logarithmically transformed. Relationships of omega-3 index and logarithmic values of inflammatory biomarkers were evaluated using Pearson correlation coefficients. Multivariable models were adjusted for age, sex, cohort (Offspring vs. Omni populations), current smoking, systolic blood pressure, body mass

index, blood levels of total cholesterol, high density lipoprotein cholesterol, triglycerides, glucose, and presence of diabetes, aspirin use (≥ 3 times per week), hormone replacement therapy, lipid drug treatment, blood pressure treatment, fish oil supplementation and/or self-reported dietary fish intake, and prevalent cardiovascular disease (myocardial infarction, stroke, congestive heart failure). Participants with prevalent CVD were excluded in a secondary analysis. We tested for effect modification by age and sex of the relations between omega-3 index and the inflammatory biomarkers. After Bonferroni correction for multiple analyses, the statistical significance was defined by two-tailed $p < 0.0013$. All statistical analyses were performed using SAS 9.2, (SAS Institute Inc., Cary, North Carolina).

Results

We evaluated 2,724 eligible participants from the Framingham Offspring and Omni Cohorts. The mean age was 66 ± 9 years for both groups combined, and 53% of participants were women. Table 1 shows the baseline clinical characteristics of the participants. Fish oil supplements were used by 11% of participants. The mean omega-3 index was 5.65 ± 1.73 for all participants.

The correlations between the omega-3 index and the inflammatory biomarkers are shown in Table 2. In age- and sex-adjusted models we observed statistically significant negative correlations between omega-3 index and all 10 inflammatory biomarkers. After multivariable adjustment, 8 correlations with the omega-3 index remained statistically significant. Correlations with monocyte chemoattractant protein-1 ($p = 0.006$) and osteoprotegerin ($p = 0.0018$) did not reach the Bonferroni critical value of $p < 0.0013$. The strongest correlations observed were for interleukin-6 ($r = -0.10$), isoprostane/creatinine ratio ($r = -0.16$), and LpPLA2 mass ($r = -0.11$). There were no significant effect modifications by sex or age (Supplemental Table 1 and 2). In secondary analysis, the removal of 163 participants with CV disease (mean omega-3 index 5.43 ± 1.59) did not materially affect the correlations (Supplemental Table 3). Reported fish oil supplementation was associated with a higher omega-3 index (mean 7.9%) and a lower concentration of CRP, but there were no significant associations with the other nine biomarkers (Supplemental Table 4).

Discussion

In our large community-based study, we found significant inverse associations between the omega-3 index and inflammatory biomarkers adjusting for multiple confounders including fish oil intake. We did not observe effect modification by age or sex of the relations between the omega-3 index and inflammatory biomarkers, and this association persisted after exclusion of individuals with a history of CVD and/or fish oil supplementation with a pill (as shown in supplemental tables 3 and 4).

Several previous studies have examined the relation between the dietary intake of ω -3 PUFA and blood levels of ω -3 PUFA to inflammatory biomarkers (Table 3). Among the dietary studies, 6 of 8 found a significant inverse association between at least one inflammatory

biomarker and ω -3 PUFA intakes, whereas in 10 of 12 biomarker-based studies, significant inverse relations for at least 1 inflammatory marker with EPA and/or DHA levels were observed. Similarly, a recent meta-analysis of 68 trials found overall significant reductions in CRP and IL-6 and marginally significant reductions in TNF α after ω -3 PUFA supplementation¹⁵. Treatment with omega-3-based pharmaceutical agents has also been shown to significantly lower LpPLA₂ levels.²⁶⁻²⁸ Reported fish oil supplementation was associated with lower concentrations of CRP in our study (Supplemental Table 4), which is consistent with data from randomized clinical trials.³¹ Our findings extend the available evidence using the omega-3 index to a larger number of inflammatory biomarkers representing major inflammatory mechanisms.

ω -3 PUFAs may affect multiple pathways resulting in the decreased production of inflammatory mediators. EPA and DHA have been shown to modulate the activity of major transcription factors controlling inflammatory responses such as nuclear factor λ B²⁹, peroxisome proliferator activated receptors^{30, 31}, and others³². The administration of ω -3 PUFAs also was associated with decreased production of potent pro-inflammatory autacoids derived from ω -6 PUFAs^{33, 34}. EPA and/or DHA have been reported by others to reduce certain interleukins and tumor necrosis factor- α ^{34, 35}, molecules produced by a wide variety of cells including those of the innate immune system, and are central to inflammatory responses³⁶⁻³⁸. Other markers assessed here, such as the isoprostanes³⁹, MCP-1⁴⁰, ICAM-1⁴¹ and LpPLA₂⁴² also play important roles in inflammatory processes and oxidative stress.

Although our findings do not establish causality, they do support the hypothesis that ω -3 PUFAs may have anti-inflammatory actions that might contribute to the clinical protective effects seen with increased intake of ω -3 rich food, especially fish. The effect of ω -3 PUFAs on inflammatory pathways may lead to their use therapeutically in diseases associated with chronic inflammation such as inflammatory bowel disease⁴³, asthma⁴⁴, rheumatoid arthritis⁴⁵ and cardiovascular disease⁴⁶. However, studies have failed to consistently demonstrate improvement in various inflammatory conditions with ω -3 PUFAs supplementation (see review by Calder⁴⁷). Thus, further studies, perhaps exploring higher doses and/or longer treatment periods, are required to more fully evaluate the role that ω -3 PUFAs may play in the management of chronic inflammatory conditions. Such studies might track the effects of change in erythrocyte ω -3 PUFAs on inflammatory biomarkers over time. Further research is also needed to better discern the biological mechanisms by which ω -3 PUFAs may modify the inflammatory cascade.

Strengths and Limitations

We examined a large community-based cohort with rigorous ascertainment of clinical risk factors, inflammatory biomarkers, and ω -3 PUFA status. The inclusion of the minority Framingham Omni cohort in addition to the Offspring cohort increases the diversity of the study population and therefore improves the generalizability of the findings. To our knowledge, our study is the largest to examine the relations between circulating ω -3 PUFA levels and inflammatory markers. The present study is also unique in including up to 10

different inflammatory biomarkers associated with widely varying pathways and phases of inflammation.

There are several limitations to our study. In an observational cross-sectional study, the associations between RBC ω -3 PUFAs with inflammatory markers cannot establish temporality or causality, and cannot exclude the possibility of residual confounding or that higher blood omega-3 levels may simply be markers of an overall healthier lifestyle. Secondly, the correlations coefficients were low to moderate in magnitude (even though highly statistically significant), we cannot establish that they are clinically relevant. Thirdly, participants were mainly middle-aged to older adults from Framingham, Massachusetts. Thus, our findings may not necessarily be representative of individuals that are younger or from other geographic areas.

Conclusion

Our community-based study identified a small-to-modest inverse association between erythrocyte ω -3 EPA+DHA levels and eight major biomarkers of inflammation, representing a wide variety of inflammation pathways. Our data are consistent with the hypothesis that long chain ω -3 PUFA may promote anti-inflammatory processes, which may result in a reduction of CV events.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding:

Dr. Benjamin is supported by 2R01HL092577; 1R01-HL64753; R01-HL076784; 1R01-1R01-AG0283211; N01-HC 25195. Dr. Vasan is supported by N01-HC25195, and Dr. Harris by R01 HL089590.

Abbreviations

RBC	red blood cell
PUFA	polyunsaturated fatty acid(s)
EPA	eicosapentaenoic acid
DHA	docosahexaenoic acid

References

1. Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and chd mortality: An updated meta-analysis of seventeen cohort studies. *Public Health Nutr.* 2012; 15:725–737. [PubMed: 21914258]
2. He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR, Goldbourt U, Greenland P. Fish consumption and incidence of stroke: A meta-analysis of cohort studies. *Stroke.* 2004; 35:1538–1542. [PubMed: 15155968]

3. Larsson SC, Orsini N. Fish consumption and the risk of stroke: A dose-response meta-analysis. *Stroke*. 2011; 42:3621–3623. [PubMed: 21903950]
4. Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, Burke GL, Carlson MC. Benefits of fatty fish on dementia risk are stronger for those without apoe epsilon4. *Neurology*. 2005; 65:1409–1414. [PubMed: 16275829]
5. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. *N Engl J Med*. 2002; 346:1113–1118. [PubMed: 11948270]
6. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. N-3 fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: A systematic review. *Am J Clin Nutr*. 2006; 84:5–17. [PubMed: 16825676]
7. Mozaffarian D, Lemaitre RN, King IB, Song X, Huang H, Sacks FM, Rimm EB, Wang M, Siscovick DS. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: A cohort study. *Ann Intern Med*. 2013; 158:515–525. [PubMed: 23546563]
8. Frostegard J. Immunity, atherosclerosis and cardiovascular disease. *BMC Med*. 2013; 11:117. [PubMed: 23635324]
9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation*. 2002; 105:1135–1143. [PubMed: 11877368]
10. Wang TJ, Gona P, Larson MG, Levy D, Benjamin EJ, Tofler GH, Jacques PF, Meigs JB, Rifai N, Selhub J, Robins SJ, Newton-Cheh C, Vasan RS. Multiple biomarkers and the risk of incident hypertension. *Hypertension*. 2007; 49:432–438. [PubMed: 17242302]
11. Fontes JD, Yamamoto JF, Larson MG, Wang N, Dallmeier D, Rienstra M, Schnabel RB, Vasan RS, Keaney JF Jr, Benjamin EJ. Clinical correlates of change in inflammatory biomarkers: The framingham heart study. *Atherosclerosis*. 2013; 228:217–223. [PubMed: 23489346]
12. Mishra M, Kumar H, Bajpai S, Singh RK, Tripathi K. Level of serum il-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes. *Diabetes Res Clin Pract*. 2011; 94:255–261. [PubMed: 21855158]
13. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and c-reactive protein to the prothrombotic state in chronic atrial fibrillation. *J Am Coll Cardiol*. 2004; 43:2075–2082. [PubMed: 15172416]
14. Kaysen GA. The microinflammatory state in uremia: Causes and potential consequences. *J Am Soc Nephrol*. 2001; 12:1549–1557. [PubMed: 11423586]
15. Li K, Huang T, Zheng J, Wu K, Li D. Effect of marine-derived n-3 polyunsaturated fatty acids on c-reactive protein, interleukin 6 and tumor necrosis factor alpha: A meta-analysis. *PLoS One*. 2014; 9:e88103. [PubMed: 24505395]
16. Steffen BT, Steffen LM, Liang S, Tracy R, Jenny NS, Tsai MY. N-3 and n-6 fatty acids are independently associated with lipoprotein-associated phospholipase a2 in the multi-ethnic study of atherosclerosis. *Br J Nutr*. 2013; 110:1664–1671. [PubMed: 23551952]
17. Steffen BT, Steffen LM, Tracy R, Siscovick D, Jacobs D, Liu K, He K, Hanson NQ, Nettleton JA, Tsai MY. Ethnicity, plasma phospholipid fatty acid composition and inflammatory/endothelial activation biomarkers in the multi-ethnic study of atherosclerosis (mesa). *Eur J Clin Nutr*. 2012; 66:600–605. [PubMed: 22215136]
18. Harris WS, Thomas RM. Biological variability of blood omega-3 biomarkers. *Clinical Biochemistry*. 2010; 43:338–340. [PubMed: 19733159]
19. Harris WS. The omega-3 index: Clinical utility for therapeutic intervention. *Curr Cardiol Rep*. 2010; 12:503–508. [PubMed: 20809235]
20. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The framingham offspring study. *Am J Epidemiol*. 1979; 110:281–290. [PubMed: 474565]
21. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, D'Agostino RB Sr, Fox CS, Larson MG, Murabito JM, O'Donnell CJ, Vasan RS, Wolf PA, Levy D. The third generation cohort of the national heart, lung, and blood institute's framingham heart study: Design,

- recruitment, and initial examination. *Am J Epidemiol.* 2007; 165:1328–1335. [PubMed: 17372189]
22. Quan SF, Howard BV, Iber C, Kiley JP, Nieto FJ, O'Connor GT, Rapoport DM, Redline S, Robbins J, Samet JM, Wahl PW. The sleep heart health study: Design, rationale, and methods. *Sleep.* 1997; 20:1077–1085. [PubMed: 9493915]
23. Harris WS, Pottala JV, Vasani RS, Larson MG, Robins SJ. Changes in erythrocyte membrane trans and marine fatty acids between 1999 and 2006 in older americans. *J Nutr.* 2012; 142:1297–1303. [PubMed: 22623386]
24. Harris WS, von Schacky C. The omega-3 index: A new risk factor for death from coronary heart disease? *Prev.Med.* 2004; 39:212–220. [PubMed: 15208005]
25. Schnabel R, Larson MG, Dupuis J, Lunetta KL, Lipinska I, Meigs JB, Yin X, Rong J, Vita JA, Newton-Cheh C, Levy D, Keaney JF Jr. Vasani RS, Mitchell GF, Benjamin EJ. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. *Hypertension.* 2008; 51:1651–1657. [PubMed: 18426996]
26. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: Effects on circulating markers of inflammation from the marine and anchor studies. *Am J Cardiovasc Drugs.* 2013; 13:37–46. [PubMed: 23325450]
27. Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein ciii, and lipoprotein-associated phospholipase a2 mass in men and women with mixed dyslipidemia. *J Clin Lipidol.* 2011; 5:483–492. [PubMed: 22108152]
28. Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins ai and ciii, and lipoprotein-associated phospholipase a(2) mass in statin-treated subjects with hypertriglyceridemia. *J Clin Lipidol.* 2009; 3:332–340. [PubMed: 21291831]
29. Massaro M, Scoditti E, Carluccio MA, Campana MC, De Caterina R. Omega-3 fatty acids, inflammation and angiogenesis: Basic mechanisms behind the cardioprotective effects of fish and fish oils. *Cell Mol Biol (Noisy-le-grand).* 2010; 56:59–82. [PubMed: 20196971]
30. Draper E, Reynolds CM, Canavan M, Mills KH, Loscher CE, Roche HM. Omega-3 fatty acids attenuate dendritic cell function via nf- κ b independent of ppar γ . *J Nutr Biochem.* 2011; 22:784–790. [PubMed: 21111596]
31. Li H, Ruan XZ, Powis SH, Fernando R, Mon WY, Wheeler DC, Moorhead JF, Varghese Z. Epa and dha reduce lps-induced inflammation responses in hk-2 cells: Evidence for a ppar- γ -dependent mechanism. *Kidney international.* 2005; 67:867–874. [PubMed: 15698426]
32. Wang T-M, Hsieh S-C, Chen J-W, Chiang A-N. Docosahexaenoic acid and eicosapentaenoic acid reduce c-reactive protein expression and stat3 activation in il-6-treated hepg2 cells. *Molecular and cellular biochemistry.* 2013; 377:97–106. [PubMed: 23361365]
33. Wada M, DeLong CJ, Hong YH, Rieke CJ, Song I, Sidhu RS, Yuan C, Warnock M, Schmaier AH, Yokoyama C, Smyth EM, Wilson SJ, FitzGerald GA, Garavito RM, Sui de X, Regan JW, Smith WL. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. *J Biol Chem.* 2007; 282:22254–22266. [PubMed: 17519235]
34. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on cox-2 expression and il-6 secretion. *Proc Natl Acad Sci U S A.* 2003; 100:1751–1756. [PubMed: 12578976]
35. Mullen A, Loscher CE, Roche HM. Anti-inflammatory effects of epa and dha are dependent upon time and dose-response elements associated with lps stimulation in thp-1-derived macrophages. *J Nutr Biochem.* 2010; 21:444–450. [PubMed: 19427777]
36. Kishimoto T. Interleukin-6: From basic science to medicine--40 years in immunology. *Annu Rev Immunol.* 2005; 23:1–21. [PubMed: 15771564]
37. Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. *J Rheumatol Suppl.* 2010; 85:27–39. [PubMed: 20436163]
38. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Takechi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (il-6) and soluble il-6 receptor after administration

- of an anti-il-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and castleman disease. *Blood*. 2008; 112:3959–3964. [PubMed: 18784373]
39. Basu S. Bioactive eicosanoids: Role of prostaglandin f(2alpha) and f(2)-isoprostanes in inflammation and oxidative stress related pathology. *Mol Cells*. 2010; 30:383–391. [PubMed: 21113821]
40. Kolattukudy PE, Niu J. Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/ccr2 pathway. *Circ Res*. 2012; 110:174–189. [PubMed: 22223213]
41. Hua S. Targeting sites of inflammation: Intercellular adhesion molecule-1 as a target for novel inflammatory therapies. *Front Pharmacol*. 2013; 4:127. [PubMed: 24109453]
42. Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase a2. *J Lipid Res*. 2012; 53:1767–1782. [PubMed: 22665167]
43. Calder PC. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. *Mol Nutr Food Res*. 2008; 52:885–897. [PubMed: 18504706]
44. Wong KW. Clinical efficacy of n-3 fatty acid supplementation in patients with asthma. *J Am Diet Assoc*. 2005; 105:98–105. [PubMed: 15635353]
45. Lee YH, Bae SC, Song GG. Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: A meta-analysis. *Arch Med Res*. 2012; 43:356–362. [PubMed: 22835600]
46. Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. *J Nutr Biochem*. 2010; 21:781–792. [PubMed: 20382009]
47. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? *Br J Clin Pharmacol*. 2013; 75:645–662. [PubMed: 22765297]
48. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among us men and women. *Circulation*. 2003; 108:155–160. [PubMed: 12821543]
49. He K, Liu K, Daviglus ML, Jenny NS, Mayer-Davis E, Jiang R, Steffen L, Siscovick D, Tsai M, Herrington D. Associations of dietary long-chain n-3 polyunsaturated fatty acids and fish with biomarkers of inflammation and endothelial activation (from the multi-ethnic study of atherosclerosis [mesa]). *Am J Cardiol*. 2009; 103:1238–1243. [PubMed: 19406265]
50. Lund AS, Hasselbalch AL, Gamborg M, Skogstrand K, Hougaard DM, Heitmann BL, Kyvik KO, Sorensen TI, Jess T. N-3 polyunsaturated fatty acids, body fat and inflammation. *Obes Facts*. 2013; 6:369–379. [PubMed: 23970146]
51. Niu K, Hozawa A, Kuriyama S, Ohmori-Matsuda K, Shimazu T, Nakaya N, Fujita K, Tsuji I, Nagatomi R. Dietary long-chain n-3 fatty acids of marine origin and serum c-reactive protein concentrations are associated in a population with a diet rich in marine products. *Am J Clin Nutr*. 2006; 84:223–229. [PubMed: 16825699]
52. Zampelas A, Panagiotakos DB, Pitsavos C, Das UN, Chrysoshoou C, Skoumas Y, Stefanadis C. Fish consumption among healthy adults is associated with decreased levels of inflammatory markers related to cardiovascular disease: The attica study. *J Am Coll Cardiol*. 2005; 46:120–124. [PubMed: 15992645]
53. Lopez-Garcia E, Schulze MB, Manson JE, Meigs JB, Albert CM, Rifai N, Willett WC, Hu FB. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. *J Nutr*. 2004; 134:1806–1811. [PubMed: 15226473]
54. Murakami K, Sasaki S, Takahashi Y, Uenishi K, Yamasaki M, Hayabuchi H, Goda T, Oka J, Baba K, Ohki K, Muramatsu K, Sugiyama Y. Total n-3 polyunsaturated fatty acid intake is inversely associated with serum c-reactive protein in young japanese women. *Nutr Res*. 2008; 28:309–314. [PubMed: 19083425]
55. Poudel-Tandukar K, Nanri A, Matsushita Y, Sasaki S, Ohta M, Sato M, Mizoue T. Dietary intakes of alpha-linolenic and linoleic acids are inversely associated with serum c-reactive protein levels among japanese men. *Nutr Res*. 2009; 29:363–370. [PubMed: 19628101]
56. Farzaneh-Far R, Harris WS, Garg S, Na B, Whooley MA. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The heart and soul study. *Atherosclerosis*. 2009; 205:538–543. [PubMed: 19185299]
57. Grenon SM, Conte MS, Nosova E, Alley H, Chong K, Harris WS, Vittinghoff E, Owens CD. Association between n-3 polyunsaturated fatty acid content of red blood cells and inflammatory

- biomarkers in patients with peripheral artery disease. *J Vasc Surg.* 2013; 58:1283–1290. [PubMed: 23830313]
58. Kalogeropoulos N, Panagiotakos DB, Pitsavos C, Chrysoshoou C, Rousinou G, Toutouza M, Stefanadis C. Unsaturated fatty acids are inversely associated and n-6/n-3 ratios are positively related to inflammation and coagulation markers in plasma of apparently healthy adults. *Clin Chim Acta.* 2010; 411:584–591. [PubMed: 20097190]
59. Baek D, Park Y. Association between erythrocyte n-3 polyunsaturated fatty acids and biomarkers of inflammation and oxidative stress in patients with and without depression. *Prostaglandins Leukot Essent Fatty Acids.* 2013; 89:291–296. [PubMed: 24113544]
60. Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F, Martin A, Andres-Lacueva C, Senin U, Guralnik JM. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. *J Clin.Endocrinol.Metab.* 2006; 91:439–446. [PubMed: 16234304]
61. Reinders I, Virtanen JK, Brouwer IA, Tuomainen TP. Association of serum n-3 polyunsaturated fatty acids with c-reactive protein in men. *Eur J Clin Nutr.* 2012; 66:736–741. [PubMed: 22113248]
62. Sekikawa A, Kadowaki T, Curb JD, Evans RW, Maegawa H, Abbott RD, Sutton-Tyrrell K, Okamura T, Shin C, Edmundowicz D, Kadota A, Choo J, El-Saed A, Ueshima H, Kuller LH, group EJS. Circulating levels of 8 cytokines and marine n-3 fatty acids and indices of obesity in japanese, white, and japanese american middle-aged men. *J Interferon Cytokine Res.* 2010; 30:541–548. [PubMed: 20626294]
63. Micallef MA, Munro IA, Garg ML. An inverse relationship between plasma n-3 fatty acids and c-reactive protein in healthy individuals. *Eur J Clin Nutr.* 2009; 63:1154–1156. [PubMed: 19352379]
64. Labonte ME, Dewailly E, Lucas M, Couture P, Lamarche B. Association of red blood cell n-3 polyunsaturated fatty acids with plasma inflammatory biomarkers among the quebec cree population. *Eur J Clin Nutr.* 2014
65. Schmidt EB, Koenig W, Khuseynova N, Christensen JH. Lipoprotein-associated phospholipase a2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. *Atherosclerosis.* 2008; 196:420–424. [PubMed: 17157859]

Highlights

- We examined cross-sectional associations of omega-3 and 10 biomarkers representing different aspects of inflammation in 2724 Framingham participants.
- We used erythrocyte membrane phospholipid DHA and EPA levels for our analyses, which provide mean levels of these fatty acids, avoiding acute fluctuations of daily intake.
- Overall, 8 out of 10 biomarkers were inversely associated with omega-3 concentrations.
- Our findings are consistent with the hypothesis that omega-3 fatty acids have anti-inflammatory properties.

Table 1

Baseline Clinical Characteristics at Examination ($n = 2,724$)

Characteristic	Value
Age, years	66±9
Female sex, %	53
Body mass index, kg/m ²	28.3±5.4
Waist circumference, inches	40.0±5.7
Smoking, %	8
Systolic blood pressure, mmHg	129±17
Diastolic blood pressure, mmHg	74±10
Total serum cholesterol, mg/dL	186±37
High density lipoprotein-C, mg/dL	57±18
Triglycerides, mg/dL	117±68
Glucose, mg/dL	107±24
Hypertension Treatment, %	49
Lipid drugs, %	43
Aspirin use 3 times week, %	44
Fish oil supplement use, %	11
Hormone replacement, % women	10
Diabetes mellitus, %	15
Prevalent cardiovascular disease, %	6

Table 2

Age- and sex-adjusted and multivariable-adjusted correlations between the inflammatory biomarkers and erythrocyte omega-3 index

Adjustment: Biomarkers	Age and sex		Multivariable *	
	r	p-value	r	p-value
C-reactive protein	-0.12	<0.001	-0.08	<0.001
Interleukin-6	-0.11	<0.001	-0.10	<0.001
Intercellular adhesion molecule-1	-0.14	<0.001	-0.08	<0.001
Urinary isoprostanes/creatinine ratio	-0.18	<0.001	-0.16	<0.001
LpPLA2 Activity	-0.10	<0.001	-0.08	<0.001
LpPLA2 Mass	-0.13	<0.001	-0.11	<0.001
Monocyte chemoattractant protein-1	-0.08	<0.001	-0.05	0.006
Osteoprotegerin	-0.07	<0.001	-0.06	0.0018
P-selectin	-0.11	<0.001	-0.06	<0.001
Tumor necrosis factor receptor 2	-0.08	<0.001	-0.08	<0.001

* Multivariable model: Age; sex; cohort (Offspring vs. Omni) current smoking; systolic blood pressure; body mass index; total cholesterol, high density lipoprotein cholesterol, triglycerides, glucose, diabetes, aspirin use (3 times per week); hormone replacement therapy; lipid lowering treatment; blood pressure, fish oil supplement or self-reported diet intake, prevalent cardiovascular disease (myocardial infarct, stroke, congestive heart failure)

Table 3

Previous observational studies on the relationship of omega-3 polyunsaturated fatty acids and inflammatory markers.

Study	Study population	Result
Omega-3 Intake		
Pischon et al. 2003 ⁴⁸	859 healthy subjects	n-3 PUFA intake inversely associated with soluble-TNF receptors 1 and 2 but not IL-6 or CRP
He et al. 2009 ⁴⁹	5,677 healthy subjects	2 of 9 markers (IL-6 and MMP-3) inversely related to n-3 PUFA intake
Lund et al. 2013 ⁵⁰	1,212 healthy subjects	n-3 PUFA intake not associated with inflammatory markers
Niu 2006 ⁵¹	971 Japanese age >70	Intake of n-3 PUFA inversely associated with CRP
Zampelas 2005 ⁵²	3042 Greek adults	Fish intake inversely associated with CRP, TNF- α , IL-6, SAA, and leukocyte count
Lopez-Garcia 2004 ⁵³	727 healthy female nurses	Compared with lowest quintile of n-3 FA intake, those in highest had lower CRP, E-selectin, sICAM-1, and s-VCAM-1
Murakami 2008 ⁵⁴	443 female Japanese dietetic students	Intake of n-3 PUFA inversely associated with CRP
Poudel-Tandukar 2009 ⁵⁵	512 healthy Japanese	Intake of EPA and DHA not associated with CRP
Omega-3 Biomarkers		
Farzaneh-Far et al. 2009 ⁵⁶	992 subjects with CAD	Erythrocyte n-3 PUFA inversely associated with CRP and IL-6
Grenon et al. 2013 ⁵⁷	64 subjects with peripheral arterial disease	Erythrocyte n-3 PUFA inversely associated with CRP but not IL-6, ICAM-1, TNF- α
Kalogeropoulos et al. 2010 ⁵⁸	374 healthy subjects	Plasma n-3 PUFA inversely associated with CRP, IL-6, TNF- α , fibrinogen
Baek et al. 2013 ⁵⁹	80 depressed Koreans vs 80 controls	Erythrocyte EPA+DHA inversely associated with iNOS, TNF- α
Ferrucci et al. 2006 ⁶⁰	1123 older Italians	Plasma DHA inversely associated with IL-6, IL-10, TGF- β , IL-1ra
Steffen et al. 2012 ^{16, 17}	2448 MESA participants	Plasma phospholipid n-3 PUFA inversely associated with IL-6, TNF-r1 and LpPLA2
Reinders et al. 2011 ⁶¹	1395 healthy Finns	Serum n-3 PUFA inversely associated with CRP
Sekikawa et al. 2010 ⁶²	297 men (Japanese in Japan; Japanese in US, and Whites in US)	Levels of 8 cytokines were not related to serum n-3 PUFA levels across cohorts
Micallef et al. 2009 ⁶³	124 healthy Australians	Plasma n-3 PUFA inversely associated with CRP
Labonte et al. 2014 ⁶⁴	744 Quebec Cree	RBC DPA n-3, but not EPA/DHA, was associated with CRP, IL-6 and TNF- α
Steffen et al. 2013 ¹⁶	2246 MESA participants	Plasma phospholipid EPA+DHA was inversely associated with LpPLA ₂ mass and activity
Schmidt et al. 2008 ⁶⁵	301 patients with CAD	Adipose tissue n-3 PUFA was inversely correlated with LpPLA ₂ mass

PUFA = polyunsaturated fatty acid; IL-6 = interleukin-6; MMP-3 = matrix metalloproteinase-3; CRP = C-reactive protein; TNF = tumor necrosis factor; ICAM = intercellular adhesion molecule; VCAM = vascular cell adhesion molecule; CAD = coronary artery disease; MESA = Multi-ethnic study of atherosclerosis